SEC Tracker
Get the app

Integra Lifesciences Holdings IART

Integra Lifesciences Holdings revenue $411.18M

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $411.18 million for the three months ended Sep 30, 2026
  2. Net income: $14.85 million for the three months ended Sep 30, 2026
  3. Diluted EPS: $0.19 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $252.26 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Integra Lifesciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$411.18M$418.76M−1.8%
Operating income and margin$18.9M · 4.6%$19.29M · 4.6%−2%, margin 0 pts
Net income$14.85M$4.48M+231%
Operating cash flow$95.98M$22.8M+321%
Cash$252.26M$214.42M+18%

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Establishment Labs Holdings ESTA public float $975M, Jun 30, 2025
  2. NovoCure NVCR public float $995M, Jun 30, 2025
  3. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  4. SI-BONE SIBN public float $800M, Jun 30, 2025
  5. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.